Fig. 7: Inhibition of YAP/TAZ activity suppresses the tumorigenic effect of BECN1-deficient adipocytes.

a Tumor volumes measured after MC-38 subcutaneously injected into 7-week-old WT, BaKO, and BYTaKO mice (WT n = 20; BaKO n = 12; BYTaKO n = 12). b Tumor volumes measured after EO771 subcutaneously injected into 7-week-old WT, BaKO, and BYTaKO (WT n = 16; BaKO n = 6; BYTaKO n = 8). c Heatmap analysis of adipogenesis and FA metabolism gene sets between WT, BaKO, and BYTaKO iWATs and their peritumoral WATs (labeled with red letter ‘T’) (n = 2 each). d Tumor volumes and weights after mammary fat pad injection of EO771 into 7- week-old mice treated with or without VP (30 mg/kg, injected every other day). VP treatment was initiated when tumors reached a volume of 150 mm³, and the mice were sacrificed on day 22 following injection (WT, n = 8; WT VP, n = 8; KO, n = 6; KO VP, n = 6). e Western blot analysis of protein lysates isolated from iWAT of Normal Chow Diet (NCD) and High Fat Diet (HFD)-fed mice. Mice were fed with HFD chow for 12 weeks. f Schematic timeline of NCD and HFD-fed mice treated with or without VP. g Tumor volumes and weights after mammary fat pad injection of EO771 into NCD or HFD-fed mice. Verteporfin(VP) treatment (30 mg/kg, injected every other day) was initiated when tumors reached a volume of 150 mm³, and the mice were sacrificed on day 26 following the injection (n = 12, each group). h Schematic illustration depicting the signaling mechanism identified in this study. Statistics were calculated using ordinary two-way ANOVA (a, b, d, g) and two-tailed unpaired students t-test (d, g). Data are shown as mean \(\pm \,\)SEM; *p\(\,\le 0.05\), **p\(\,\le 0.01\), ***p\(\,\le 0.001\). Western blot results are representatives of at least three independent experiments.